Antibody-Based Therapy is Poised to be the Fastest-Growing Segment of New Cancer Drug Development, page-22

DJ,

Fat Harry agrees. However, there are mitigating circumstances that may suggest that, in "usual" situations, SM6 may be more effective than noted for MM.
1) The patients were already extremely ill; having exhausted all previous therapies.
2) The doses of SM6 were very small, at least for the first 3 cohorts. Still, positive changes were noted. The maximum dose was only 6mg/kg (from memory).
3) SM6 was given alone.
4) A maximum of 2 "rounds" of therapy were given.

So, if we imagine a group of MM patients who receive SM6:
1) In the early stage of the disease, while the patient still has some reserves of strength left.
2) At a higher dose rate.
3) Concurrently with other therapies.
4) Possibly more "rounds".

The results may be much more positive!

The Cat